Abstract:This study explores the role of Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) in conferring methotrexate (MTX) resistance in breast cancer cells. Through a series of experiments involving human breast cancer cell lines, the research demonstrates that PCMT1 is upregulated in MTX‐resistant cells. By employing siRNA techniques to silence the PCMT1 gene, the study observed a significant reduction in cell proliferation, migration, and invasion, alongside a decreased activation of the PI3K/Akt/STMN1 pathway, known for its role in cancer cell survival. Overall, the inhibition of PCMT1 enhanced the sensitivity of breast cancer cells to MTX, suggesting that PCMT1 might be a viable therapeutic target to overcome resistance. This study aimed to investigate whether silencing Protein L‐isoaspartate (D‐aspartate) O‐methyltransferase (PCMT1) expression can enhance the sensitivity of breast cancer cells to paclitaxel and its possible mechanism. Tumor tissues and adjacent histologically normal tissues were collected from patients with breast cancer admitted to our hospital. Human normal breast epithelial cells MCF10A, human breast cancer cells MCF‐7, and paclitaxel‐resistant breast cancer cells MCF‐7/PR were purchased. MCF‐7/PR cells were further grouped into negative control (NC) group, si‐PCMT1 group (transfected with si‐PCMT1), 740Y‐P group (treated with 740Y‐P, an activator of phosphatidylinositol 3‐kinase (PI3K)/ v‐Akt Murine Thymoma Viral Oncogene (AKT) signaling pathway), and si‐PCMT1 + 740Y‐P group (transfected with si‐PCMT1 and then treated with 740Y‐P). The expression level of PCMT1 in tissues and cells was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR). Western blot analysis was used to detect the protein expression level of PCMT1 in tissues and cells as well as the protein level of p‐PI3K, PI3K, p‐Akt, Akt, and Stathmin1 (STMN1) in cells. 3‐(4,5)‐dimethylthiahiazo(‐z‐y1)‐3,5‐di‐phenytetrazoliumromide (MTT) and colony formation assays were used to determine cell viability, scratch assay was used to assess the migration ability of cells, and Transwell assay was used to assess the invasion ability of cells. The expression of PCMT1 was remarkably up‐regulated in breast cancer tissues and MCF‐7/PR cells. Silencing PCMT1 expression significantly inhibited the proliferation, migration, and invasion of MCF‐7/PR cells, and alleviated the resistance of cancer cells to paclitaxel. Additionally, silencing PCMT1 expression also inhibited the activation of PI3K/Akt/STMN1 pathway in MCF‐7/PR cells, while activating PI3K/Akt/STMN1 pathway significantly reversed the effect of silencing PCMT1 expression on MCF‐7/PR cells. PCMT1 is highly expressed in breast cancer tissues and MCF‐7/PR cells, and silencing PCMT1 expression can not only inhibit the development of breast cancer but also enhance paclitaxel sensitivity. Its mechanism of action may be achieved by inhibiting PI3K/Akt/STMN1 signaling.

Targeted Inhibition of Notch1 Gene Enhances the Killing Effects of Paclitaxel on Triple Negative Breast Cancer Cells.

The Inhibiting Effect of Combination of Allicin with Paclitaxel on Proliferation of Gastric Cancer Cells and Promotion of Apoptosis

Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial–mesenchymal transition process

Overexpression of Centrosomal Protein Nlp Confers Breast Carcinoma Resistance to Paclitaxel

&Lt;p>integrative Gene Expression Profiling Reveals That Dysregulated Triple Micrornas Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Co-Targeting MAPT</p>

Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β-Tubulin in Triple-Negative Breast Cancer

Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer

Enhancing Chemotherapy Efficacy: Investigating the Synergistic Impact of Paclitaxel and cd73 Gene Suppression on Breast Cancer Cell Proliferation and Migration

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway

Enhanced Apoptotic Effects in MDA-MB-231 Triple-Negative Breast Cancer Cells Through a Synergistic Action of Luteolin and Paclitaxel

Downregulated Mucin 1 alleviates paclitaxel resistance in non‐small cell lung cancer cells

miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer

Targeting NOTCH2-JAG1 juxtacrine signaling reverses macrophage-mediated tumor resistance to taxol

Study On Inhibitory Effect Of Paclitaxel On Mek And Erk Protein Overexpression And Activation In Different Breast Cancer Cell Lines

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells Via Direct Suppression of JAG1/Notch1 Axis

Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway

IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells

Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer

Sensitization of Decitabine Combined with Paclitaxel on Proliferation Inhibition and Apoptosis Induction of Paclitaxel-resistant MCF-7 Cells